Thursday, March 28, 2024
11:10 AM EST – Theratechnologies Inc. : Today announced two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, demonstrating the potential of its SORT1+ Technology™ platform – including novel camptothecin-peptide conjugates and its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), as anticancer treatments. The AACR meeting is taking place April 5-10 in San Diego, CA. Theratechnologies Inc. (T.TH ) shares were up $0.05 at 2.03.
Stocks in Play: Theratechnologies Inc., Thu, 28 Mar 2024 11:12:06 EST